RAVI GOKLANEY: Open Payments
NPI 1437212636 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$88,734 in 146 payments from 11 companies in 2025. Trend: 2023 $14,542 · 2024 $12,922 · 2025 $88,734
Speaker / faculty: $48,710Consulting: $28,369Travel & lodging: $6,353Food & beverage: $5,302
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 55 | $40,547 |
| Alkermes, Inc. | 48 | $29,935 |
| E.R. Squibb & Sons, L.L.C. | 14 | $8,702 |
| Otsuka America Pharmaceutical, Inc. | 11 | $8,363 |
| Teva Pharmaceuticals USA, Inc. | 8 | $424 |
| Janssen Pharmaceuticals, Inc | 3 | $271 |
| Vanda Pharmaceuticals Inc. | 2 | $150 |
| Neurocrine BioSciences, Inc. | 2 | $137 |
| ABBVIE INC. | 1 | $125 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $62 |
Products named: CAPLYTA, LYBALVI, REXULTI, ARISTADA, UZEDY, INVEGA SUSTENNA, COBENFY, FANAPT.
Industry payments across CA — which companies pay providers there.
